Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
出版年份 2021 全文链接
标题
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
作者
关键词
-
出版物
ESMO Open
Volume 6, Issue 3, Pages 100114
出版商
Elsevier BV
发表日期
2021-04-23
DOI
10.1016/j.esmoop.2021.100114
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016
- (2020) Elise Deluche et al. EUROPEAN JOURNAL OF CANCER
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
- (2020) Sandra M Swain et al. LANCET ONCOLOGY
- Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2–targeted treatments: Results from the french personalized reimbursement model database (2011–2018)
- (2020) Paul Cottu et al. EUROPEAN JOURNAL OF CANCER
- The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)
- (2019) David Pérol et al. BMJ Open
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
- (2019) Richard Gray et al. LANCET
- Does adjuvant therapy reduce post-metastatic survival?
- (2019) M K Fink ANNALS OF ONCOLOGY
- Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program
- (2019) William Jacot et al. INTERNATIONAL JOURNAL OF CANCER
- Recommandations du GEFPICS pour la prise en charge des prélèvements dans le cadre du traitement néoadjuvant du cancer du sein
- (2019) Aurélie Maran-Gonzalez et al. ANNALES DE PATHOLOGIE
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015)
- (2018) Fatima Cardoso et al. BREAST
- Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
- (2018) Elisa Gobbini et al. EUROPEAN JOURNAL OF CANCER
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
- (2018) Michael Lux et al. Cancers
- Real-world Data for Clinical Evidence Generation in Oncology
- (2017) Sean Khozin et al. JNCI-Journal of the National Cancer Institute
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- Real-world Data for Clinical Evidence Generation in Oncology
- (2017) Sean Khozin et al. JNCI-Journal of the National Cancer Institute
- 350O_PRFINAL OVERALL SURVIVAL (OS) ANALYSIS FROM THE CLEOPATRA STUDY OF FIRST-LINE (1L) PERTUZUMAB (PTZ), TRASTUZUMAB (T), AND DOCETAXEL (D) IN PATIENTS (PTS) WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC)
- (2017) S. Swain et al. ANNALS OF ONCOLOGY
- Universalism, Responsiveness, Sustainability — Regulating the French Health Care System
- (2016) Monika Steffen NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-World Evidence — What Is It and What Can It Tell Us?
- (2016) Rachel E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early market access of cancer drugs in the EU
- (2015) J. Martinalbo et al. ANNALS OF ONCOLOGY
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- Adjuvant Therapy-Related Shortening of Survival (ATRESS): An Underrated Phenomenon
- (2015) M. K. Fink et al. ONCOLOGIST
- Recommandations du GEFPICS concernant la phase pré-analytique pour l’évaluation de HER2 et des récepteurs hormonaux dans le cancer du sein : mise à jour 2014
- (2014) Gaëtan MacGrogan et al. ANNALES DE PATHOLOGIE
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Explaining the difference in prognosis between screen-detected and symptomatic breast cancers
- (2011) P C Allgood et al. BRITISH JOURNAL OF CANCER
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Correcting for Lead Time and Length Bias in Estimating the Effect of Screen Detection on Cancer Survival
- (2008) S. W. Duffy et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now